Our results showing a reduced growth rate of oxaliplatin-treated HCT116 cells under hypoxia, which is not evident in HT29, support further examination into whether hypoxia alters oxaliplatin-induced p53 activation in CRC cells. The gene discussed is TP53; the disease is colorectal carcinoma.